Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway

被引:57
|
作者
Zhao, Shengqiang [1 ]
Wang, Jing [1 ]
Qin, Chengyong [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Gastroenterol, Jinan 250100, Peoples R China
关键词
Intrahepatic cholangiocarcinoma (IHCC); CXC chemokine ligand-12 (CXCL12)/chemokine receptor type 4 (CXCR4); Prognosis; Metastasis; Wnt pathway; EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; CHEMOKINE RECEPTOR CXCR4; HEPATIC STELLATE CELLS; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR-BETA; BREAST-CANCER; TUMOR PROGRESSION; WNT/BETA-CATENIN; FACTOR-ALPHA;
D O I
10.1186/s13046-014-0103-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Intrahepatic cholangiocarcinoma (IHCC) is the second most frequent primary malignant liver tumor following hepatocellular carcinoma. It is a highly fatal disease and has few therapeutics. The CXC chemokine ligand-12 (CXCL12)/CXC chemokine receptor type 4 (CXCR4) axis has been shown to be involved in tumorgenesis, proliferation, and angiogenesis in a variety of cancers including IHCC. However, its prognostic significance in IHCC is unclear. The purpose of this study was to examine the functional role of CXCR4 in the progression and metastasis of IHCC and explore the underlying mechanism. Methods: The CXCR4 expression, overall survival, and the clinical characteristics including age, sex, differentiation degree, tumor size, vascular invasion, lymph node metastasis, TNM stage, and T stage were analyzed for 122 IHCC patients. Short hairpin RNA (shRNA) against CXCR4 was used to disrupt the CXCL12/CXCR4 signal transduction pathways in IHCC cell lines. In vitro assays, including CCK-8 assay, flow cytometry, and colony formation assay, and in vivo tumor formation assay were utilized to detect the cell phenotype of CXCR4 knockdown cells. Transwell and wound healing assays were used to examine the IHCC cell invasion and migration ability. The Wnt pathway was assessed by Western blot and beta-Catenin/Tcf transcription reporter assay. Results: We demonstrated that CXCR4 expression was closely correlated with IHCC progression and metastasis characteristics. The overall survival of patients with high CXCR4 expression was significantly lower than that of patients with low CXCR4 expression. Furthermore, we showed that the abrogation of CXCR4 had significantly negative influence on the IHCC cell phenotype, including in vitro cell proliferation, cell cycle, colony formation, cell invasion, and in vivo tumorigenicity. In addition, CXCR4 knockdown downregulated Wnt target genes and mesenchymal markers such as Vimentin and Slug. Conclusions: In conclusion, our result shows that high CXCR4 expression is associated with IHCC progression and metastasis via the canonical Wnt pathway, suggesting that CXCR4 may serve as a promising therapeutic target for IHCC.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] An emerging paradigm of Cxcl12/Cxcr4 involvement in breast cancer metastasis
    Lagou, Maria K.
    Rivera, Luis G.
    Duran, Camille E.
    Burt, Joseph
    Chen, Xiaoming
    Lin, Yu
    Eddy, Robert
    Harney, Allison S.
    Entenberg, David
    Condeelis, John S.
    Oktay, Maja H.
    Karagiannis, George S.
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways
    Drury, Luke J.
    Ziarek, Joshua J.
    Gravel, Stephanie
    Veldkamp, Christopher T.
    Takekoshi, Tomonori
    Hwang, Samuel T.
    Heveker, Nikolaus
    Volkman, Brian F.
    Dwinell, Michael B.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (43) : 17655 - 17660
  • [33] An emerging paradigm of Cxcl12 & Cxcr4 involvement in breast cancer metastasis
    Anastasiadou, Dimitra P.
    Sanchez, Luis R.
    Duran, Camille L.
    Burt, Joseph
    Chen, Xiaoming
    Lin, Yu
    Eddy, Robert
    Harney, Allison S.
    Entenberg, David
    Condeelis, John S.
    Oktay, Maja H.
    Karagiannis, George S.
    CANCER RESEARCH, 2023, 83 (07)
  • [34] An Emerging and Previously Unrecognized Paradigm of Cxcl12/ Cxcr4 Pathway Implication in Breast Cancer Metastasis
    Lagou, Maria K.
    Sanchez, Luis R.
    Duran, Camille L.
    Burt, Joseph
    Chen, Xiaoming
    Lin, Yu
    Eddy, Robert
    Harney, Allison S.
    Entenberg, David
    Condeelis, John S.
    Oktay, Maja H.
    Karagiannis, George S.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [35] PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling
    Conley-LaComb, M. Katie
    Saliganan, Allen
    Kandagatla, Pridvi
    Chen, Yong Q.
    Cher, Michael L.
    Chinni, Sreenivasa R.
    MOLECULAR CANCER, 2013, 12
  • [36] PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling
    M Katie Conley-LaComb
    Allen Saliganan
    Pridvi Kandagatla
    Yong Q Chen
    Michael L Cher
    Sreenivasa R Chinni
    Molecular Cancer, 12
  • [37] Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides
    Daggett, R. N.
    Kurata, M.
    Abe, S.
    Onishi, I.
    Miura, K.
    Sawada, Y.
    Tanizawa, T.
    Kitagawa, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (04) : 722 - 731
  • [38] Inflammation-Induced Pericyte Dysfunction Is Abrogated by Interfering with the CXCL12/CXCR4 Signaling Pathway
    Johnson, J.
    Shammout, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [39] Erratum to: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
    Xueqing Sun
    Guangcun Cheng
    Mingang Hao
    Jianghua Zheng
    Xiaoming Zhou
    Jian Zhang
    Russell S. Taichman
    Kenneth J. Pienta
    Jianhua Wang
    Cancer and Metastasis Reviews, 2011, 30 : 269 - 270
  • [40] CXCR4 and CXCL12 signaling regulates the development of extrinsic innervation to the colorectum
    Halasy, Viktoria
    Szocs, Emoke
    Soos, Adam
    Kovacs, Tamas
    Pecsenye-Fejszak, Nora
    Hotta, Ryo
    Goldstein, Allan M.
    Nagy, Nandor
    DEVELOPMENT, 2023, 150 (08):